Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition

ConclusionFrom our results we conclude that dual treatment with SHK and TMZ may constitute a powerful new tool for GBM treatment by reducing therapy resistance and tumor recurrence.

http://link.springer.com/10.1007/s13402-017-0320-1

Source: Cellular Oncology - April 11, 2017 Category: Cancer & Oncology Source Type: research